Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Reid W Merryman

Showing results (31-40 of 42) with videos related to

Pageof 5
Sort By:
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Blood|January 12, 2017
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaReid W Merryman, Haesook T Kim, Pier Luigi Zinzani, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell LymphomaEdward R Scheffer Cliff, Guido D Pelaez, Fei Wan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 5

Showing results (31-40 of 42) with videos related to

Sort By:
Pageof 5
Blood Advances|January 10, 2020
PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantationMatthew J Frigault, Philippe Armand, Robert A Redd, et al.
Blood Advances|November 18, 2022
Minimal residual disease in patients with diffuse large B-cell lymphoma undergoing autologous stem cell transplantationReid W Merryman, Robert A Redd, Eleanor Taranto, et al.
Blood|January 12, 2017
Safety and efficacy of allogeneic hematopoietic stem cell transplant after PD-1 blockade in relapsed/refractory lymphomaReid W Merryman, Haesook T Kim, Pier Luigi Zinzani, et al.
The Oncologist|April 11, 2020
Impact of Treatment Beyond Progression with Immune Checkpoint Blockade in Hodgkin LymphomaReid W Merryman, Nicole A Carreau, Ranjana H Advani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
Cell-of-Origin Subtype Predicts Response to Polatuzumab Vedotin in Large B-cell LymphomaEdward R Scheffer Cliff, Guido D Pelaez, Fei Wan, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 31, 2016
Relapsed or Refractory Double-Expressor and Double-Hit Lymphomas Have Inferior Progression-Free Survival After Autologous Stem-Cell TransplantationAlex F Herrera, Matthew Mei, Lawrence Low, et al.
Blood Advances|August 5, 2025
Treatment and outcomes of progression of disease post-CAR T-cell therapy in mantle cell lymphoma: a multicenter analysisZachary D Epstein-Peterson, Anath Christopher Lionel, Ashlee Joseph, et al.
Blood Advances|March 12, 2021
Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphomaReid W Merryman, Robert A Redd, Taiga Nishihori, et al.
Blood Advances|February 24, 2026
Benefit of rituximab maintenance after first-line bendamustine-rituximab in patients with mantle cell lymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Blood Advances|December 11, 2025
Benefit of Rituximab Maintenance After First-line Bendamustine-Rituximab in Patients with Mantle Cell LymphomaYucai Wang, Melissa C Larson, Steven R Hwang, et al.
Pageof 5